Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study

Background Evidence suggests that schizophrenia may have a better outcome for individuals living in low- and middle-income countries compared with affluent settings. Aims To determine the frequency of symptom and functional remission in out-patients with schizophrenia in different regions of the wor...

ver descrição completa

Detalhes bibliográficos
Autores: Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2011
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p979
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=979
https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/crossnational-clinical-and-functional-remission-rates-worldwide-schizophrenia-outpatient-health-outcomes-wsoho-study/7C253ED17E105A494EDD6079AABA916B
Access Level:acceso abierto
Palavra-chave:TERM FOLLOW-UP
LONG-TERM
1ST-EPISODE SCHIZOPHRENIA
DEPRESSIVE SYMPTOMS
UNTREATED PSYCHOSIS
RECOVERY
DISORDERS
ILLNESS
PROGNOSIS
HALOPERIDOL
Descrição
Resumo:Background Evidence suggests that schizophrenia may have a better outcome for individuals living in low- and middle-income countries compared with affluent settings. Aims To determine the frequency of symptom and functional remission in out-patients with schizophrenia in different regions of the world. Method Using data from the Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO) study we measured clinical and functional remission in out-patients with schizophrenia in different regions of the world, and examined sociodemographic and clinical factors associated with these outcomes. The 11 078 participants analysed from 37 participating countries were grouped into 6 regions: South Europe, North Europe, Central and Eastern Europe, Latin America, North Africa and Middle East, and East Asia. Results In total, 66.1% achieved clinical remission during the 3-year follow-up (range: 60.1% in North Europe to 84.4% in East Asia) and 25.4% achieved functional remission (range: 17.8% in North Africa and Middle East to 35.0% in North Europe). Regional differences were not explained by participants' clinical characteristics. Baseline social functioning, being female and previously untreated were consistent predictors of remission across regions. Conclusions Clinical outcomes of schizophrenia seem to be worse in Europe compared with other regions. However, functional remission follows a different pattern.